Abstract 117P
Background
Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer (GC) with hepatocyte-like differentiation and a dismal prognosis. Although HAS has different histological and molecular properties and more aggressive biological behavior, most patients with HAS still receive the same regimen as usual GC. A comprehensive understanding of the molecular properties of HAS may provide insights into personalized diagnosis and treatment, however, this area is under-studied.
Methods
We aimed to explore methylome and transcriptome profiling of HAS in a relatively precise scenario. The laser capture microdissection (LCM) was used to isolate thirty-two formalin fixed paraffin-embedded (FFPE) tissue into gastric adenocarcinoma section (GAC) and hepatocellular-like section (HAS). According to the manufacturer's protocol, DNA-associated methylation sequencing and RNA-associated transcriptome sequencing were performed.
Results
With Laser-Capture Microdissection (LCM) technique, we separate HAS FFPE sample into gastric adenocarcinoma component (GAC) and HAS component. The whole genome RNAseq and methylation sequencing (GMseq) were used to explore HAS expression patterns and methylation modification profile. We found that differentially methylated cytosine was effective in distinguishing GAC from HAS, and stem cell-related gene expression and pathway enrichment were higher in GAC than in HAS. Correspondingly, HAS showed TNFSF15 gene significantly hypermethylation and lower expression features. In addition, in vivo xenograft models derived from TNFSF15 knockout cells showed higher aggressiveness and hepatocyte-like gene expression. Our study sheds light on the critical role of TNFSF15 in HAS transdifferentiation, and intervening methylation of TNFSF15 may be a clinical option to improve prognosis and reduce metastasis.
Conclusions
In summary, we found that the GAC component has the expression features of pluripotent stem cells and mesothelial cells, and the HAS component has the features of hepatoblast and mature hepatocytes. We propose that GAC mesoderm and endoderm dedifferentiation bias TME as the key role to HAS transdifferentiation and TNFSF15 may be a key regulatory factor in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Presenter: Vincent de Jager
Session: Poster session 08
114P - Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma
Presenter: Oscar Gerardo Arrieta Rodriguez
Session: Poster session 08
115P - Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Presenter: Marie Morfouace
Session: Poster session 08
116P - Single-cell RNA sequencing reveals a subset of FSIP1 cancer cells and verified its value of prognosis in lung adenocarcinoma
Presenter: Xiaochen Zhang
Session: Poster session 08
Resources:
Abstract
118P - Comparative analysis of DNA and RNA-based NGS for detecting MET exon 14 skipping mutation in pan-solid tumor samples
Presenter: Ruijun Cai
Session: Poster session 08
119P - Predicting the pathogenicity of novel fusion genes and explaining reasons using a large language model: A focused assessment
Presenter: Katsuhiko Murakami
Session: Poster session 08
120P - A prospective comparative evaluation of automatic trial match tools in a molecular tumor board
Presenter: Lilia GUEGUEN
Session: Poster session 08
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Presenter: Florian Moik
Session: Poster session 08